<DOC>
	<DOCNO>NCT00960804</DOCNO>
	<brief_summary>Tanezumab , administer 1 1/2 year , reduces pain osteoarthritis without affect nerve impulse transmit sensory nerve</brief_summary>
	<brief_title>Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients</brief_title>
	<detailed_description>This study terminate 11 Nov 2010 follow US FDA clinical hold tanezumab osteoarthritis clinical study halt dose enrollment patient 23 June 2010 potential safety issue .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Patients must consent write participate study . Patients must willing comply study visit schedule study requirement , include , woman childbearing potential male patient female partner childbearing potential , use 2 form birth control , one barrier method . Patients must participate A4091026 study . Withdrawn A4091026 study adverse event serious adverse event . Pregnant woman , lactate mother , woman suspect pregnant , woman wish pregnant course clinical study . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>OA</keyword>
</DOC>